CLINICAL TRIALS PROFILE FOR OTEZLA
✉ Email this page to a colleague
All Clinical Trials for OTEZLA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Amgen | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Celgene Corporation | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
NCT00773734 ↗ | Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) | Completed | Amgen | Phase 2 | 2008-09-01 | The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OTEZLA
Condition Name
Clinical Trial Locations for OTEZLA
Trials by Country
Clinical Trial Progress for OTEZLA
Clinical Trial Phase
Clinical Trial Sponsors for OTEZLA
Sponsor Name